Trial Profile
A Study to Evaluate the Safety of Dabrafenib Alone or in Combination With Trametinib in Patients With Metastatic Melanoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Apr 2016
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 04 Apr 2016 New trial record
- 08 Mar 2016 Results presented at the 74th Annual Meeting of the American Academy of Dermatology